Get the Stockscreener App
228.49
0.54%
-1.25
Pre-market:
228.47
-0.02
-0.01%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $228.49, with a volume of 2.83M.
It is down -0.54% in the last 24 hours and up +0.35% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$229.74
Open:
$229.74
24h Volume:
2.83M
Relative Volume:
0.50
Market Cap:
$403.83B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
172.41
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-0.61%
1M Performance:
+0.35%
6M Performance:
+23.10%
1Y Performance:
+28.58%
1-Day Range:
$228.43
$230.25
1-Week Range:
$228.43
$232.01
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
228.49 | 406.04B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,074.68 | 966.40B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.95 | 498.51B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
137.87 | 266.17B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
105.26 | 263.24B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
What to Expect From AbbVie's Next Quarterly Earnings Report - Barchart.com
Generali Asset Management SPA SGR Decreases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Banque Pictet & Cie SA Has $77.33 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026 - Seeking Alpha
AbbVie stock ends 2025 lower as markets shut for New Year — what ABBV investors watch next - ts2.tech
Miracle Mile Advisors LLC Has $13.65 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Los Angeles Capital Management LLC - MarketBeat
Nicholas Wealth LLC. Cuts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Moody Lynn & Lieberson LLC Has $42.48 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Allspring Global Investments Holdings LLC Grows Position in AbbVie Inc. $ABBV - MarketBeat
The Truth About AbbVie Inc (ABBV): Quiet Pharma Giant, Loud Money Moves - AD HOC NEWS
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share - Insider Monkey
The Truth About AbbVie Inc: Is ABBV the Sleeper Stock Gen Z Is Sleeping On? - AD HOC NEWS
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance
VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Smith Salley Wealth Management - MarketBeat
Generate Investment Management Ltd Increases Position in AbbVie Inc. $ABBV - MarketBeat
Simplify Asset Management Inc. Boosts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Calamos Wealth Management LLC Has $3.41 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Brendel Financial Advisors LLC - MarketBeat
Diversified Trust Co Purchases 10,891 Shares of AbbVie Inc. $ABBV - MarketBeat
Zelgen Biopharma says it signs strategic partnership with Abbvie for development and commercialisation of Alveltamig - marketscreener.com
AbbVie (ABBV): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
BofA cuts AbbVie (ABBV) target while maintaining neutral view - MSN
BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View - Insider Monkey
3 No-Brainer Dividend Stocks to Buy Right Now - The Motley Fool
AbbVie stock slips today as Fed minutes loom in thin year-end trade - ts2.tech
Judge Halts US Drug Discount Overhaul, Blocks 340B Rebate Plan - Benzinga
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains - TradingView — Track All Markets
Fort Washington Investment Advisors Inc. OH Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts - ts2.tech
AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching - ts2.tech
Long-Term Stock Portfolio: 10 Best Stocks for the Next Decade - Insider Monkey
AbbVie Stock: Dividend Giant Balances Humira Cliff, Immunology Momentum and Wall Street Optimism - AD HOC NEWS
Sowell Financial Services LLC Sells 8,716 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Sapient Capital LLC - MarketBeat
Meyer Handelman Co. Has $39.35 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Carnegie Investment Counsel Purchases 25,146 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (NYSE:ABBV) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus - ts2.tech
Is AbbVie a Buy, Sell, or Hold in 2026? - Finviz
AbbVie Inc. $ABBV Shares Sold by Highland Capital Management LLC - MarketBeat
Aug Momentum: How AbbVie Inc stock reacts to job market dataJuly 2025 Weekly Recap & Reliable Price Action Trade Plans - moha.gov.vn
5,829 Shares in AbbVie Inc. $ABBV Bought by Regent Peak Wealth Advisors LLC - MarketBeat
World Investment Advisors Increases Position in AbbVie Inc. $ABBV - MarketBeat
United States Semaglutide Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, Eli Lilly and Co, AstraZeneca, Biocon, Johnson and Johnson, Pfizer, AbbVie, and SanofiResearchAndMarkets.com - The AI Journal
AbbVie Inc. $ABBV Shares Sold by Pacer Advisors Inc. - MarketBeat
Cwm LLC Has $87.91 Million Position in AbbVie Inc. $ABBV - MarketBeat
Clayton Financial Group LLC Takes $1.43 Million Position in AbbVie Inc. $ABBV - MarketBeat
The Zacks Analyst Blog AbbVie, The Coca-Cola, Chevron, ImmuCell and Precipio - Yahoo Finance
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):